Navigation Links
Statement From Sequella Founder and CEO, Dr. Carol Nacy at the 'Stop TB' Meeting in Brazil on the Eve of World TB Day
Date:3/23/2009

RIO DE JANEIRO, Brazil, March 23 /PRNewswire-USNewswire/ -- "With multidrug (MDR) and extremely drug (XDR) resistant tuberculosis on the rise, the world-wide financial crisis is of major concern to the international health community," said Dr. Carol Nacy, CEO of Sequella. "The Global Fund to fight HIV, malaria, and TB is running a huge deficit, and public health officials fear that any gains of the last 10 years in control of TB, especially in HIV-infected patients, will be lost. The specter of untreatable TB hangs like a pall over the STOP TB Partnership meeting in Rio de Janeiro, as patient advocates and health ministers, companies and non-governmental organizations, gather to determine how best to work together to even maintain the status quo."

About Sequella (www.sequella.com)

Sequella is a clinical stage biopharmaceutical company focused on commercializing improved treatments for infectious diseases of epidemic potential. The company leverages its global influence, R&D platforms and infectious disease expertise to proactively address emerging health threats. Through focused execution, clear commercialization pathways, and strategic partnerships, Sequella intends to commercialize a broad product portfolio designed to treat global health threats with significant market opportunity.

Sequella has both drugs and diagnostics in various stages of development. The company's lead drug candidate, SQ109 is a new diamine antibiotic intended to replace one or more of the current first-line anti-TB drugs and simplify patient therapy. SQ109 was granted U.S. FDA Fast Track designation and FDA/EMEA Orphan Drug Designation in 2007. SQ109 shows activity against drug sensitive and multi-drug resistant (MDR and XDR) Mycobacterium tuberculosis, the causative agent of TB. SQ109 is due to begin a Phase 1B study to assess safety and pharmacokinetics of multiple doses of SQ109 in healthy subjects.

SQ609, a second compound being developed by Sequella is a novel small molecule dipiperidine antibiotic selected from a proprietary chemical library of over 250,000 new molecular entities with activity for a broad spectrum of infectious diseases. Orally bioavailable with excellent single-drug activity against Mycobacterium tuberculosis in vitro and in vivo, SQ609 has demonstrated synergistic activity with several front-line antitubercular drugs and can be readily synthesized on a large scale. Sequella recently received a $300,000 Small Business Innovation Research (SBIR) Phase I Grant from the National Institute of Allergy and Infectious Disease (NIAID), National Institutes of Health (NIH), to further fund the preclinical development this lead dipiperidine drug compound, SQ609.

Sequella is currently undergoing pivotal Phase III TB Patch trials. The TB Patch is a non-invasive point-of-care test used to detect active TB infection. The TB Patch requires no sample or laboratory processing and provides results in less than four days. Sequella holds the worldwide licensing rights for the TB Patch outside of Japan.

Forward-Looking Statement

This press release contains forward-looking statements that are subject to risks and uncertainties, and includes statements that are not historical facts. Actual results could differ significantly from results discussed. Sequella disclaims any intent or obligation to update forward-looking statements, except as required by law.


'/>"/>
SOURCE Sequella, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related medicine news :

1. Statement of Eli Lilly and Company on Dr. David Egilman Settlement:
2. Takeda statement on ACTOS meta-analysis published in the Journal of the American Medical Association
3. Takeda Statement on ACTOS(R) (Pioglitazone HCl) Meta-Analysis Published in the Journal of the American Medical Association
4. Statement by Mike Leavitt Secretary of Health and Human Services on the United States-China Bilateral Meetings on Food and Drug Safety
5. Statement by Oscar S. Wyatt, Jr.
6. Statement from Employment Policies Institute on Senator Hillary Clintons Health Care Plan
7. Pelosi Statement on Proposed Entitlement Task Force
8. Statement by Robert Greenstein, Executive Director of the Center on Budget and Policy Priorities, on the New Congressional SCHIP Agreement
9. Statement on House/Senate Agreement on SCHIP Legislation
10. Statement from the Alliance for Quality Nursing Home Care
11. Produce for Better Health Foundation Releases Statement on Study Saying Fruit & Vegetable Consumption Not Strongly Associated With Colon Cancer Risk
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/13/2017)... ... ... As health professionals work to improve their approach to healthcare, there is a ... filling out a survey; in many cases health professionals and patients are working together ... research on the importance of active engagement with patients and members of the public ...
(Date:10/13/2017)... ... October 13, 2017 , ... ... Randall, PharmD ‘17, and Jennifer Huggins, PharmD ’17, along with clinical associate ... primary prevention of cardiovascular diseases during the 15th Annual Women’s Health Conference. ...
(Date:10/13/2017)... ... October 13, 2017 , ... Ellevate Network, the leading network ... advocate for action towards gender equality at their inaugural Summit in New York City ... and reached a social audience of over 3 million. To watch the Mobilize Women ...
(Date:10/13/2017)... ... October 13, 2017 , ... “The Journey: From the Mountains to the Mission ... lost souls in the Philippines. “The Journey: From the Mountains to the Mission Field” ... the Bible. She has taught all ages and currently teaches a class of ladies ...
(Date:10/12/2017)... Wis. (PRWEB) , ... October 12, 2017 , ... ... standard products to meet the demand of today’s consumer and regulatory authorities worldwide. ... of probiotic experts and tested to meet the highest standard. , These ...
Breaking Medicine News(10 mins):
(Date:10/4/2017)... Korea , Oct. 4, 2017  South Korean-based ... next-generation CPR training aide "cprCUBE" on Kickstarter. The device ... compression during cardiac arrests with better efficiency compared to ... also offers real-time feedback on efficacy of the compression ... crowdfunding campaign has a goal to raise $5,000. ...
(Date:10/2/2017)... , Oct. 2, 2017 Diplomat Pharmacy, Inc. ... Day Software and Consulting, LLC , and named its ... Software, based in Tennessee , will ... Day expands EnvoyHealth,s service offerings for health care partners ... "In an interoperable world, ...
(Date:10/2/2017)... Labs announces the European launch of their new low volume, high ... in Cambridge, U.K on October 4th. The ... with unprecedented speed and sensitivity while using far less sample volume ... ... ...
Breaking Medicine Technology: